Windtree Therapeutics Announces New Istaroxime Expedited Review Filing of Patent
Excerpt from the Press Release:
WARRINGTON, Pa., April 19, 2021 /PRNewswire/ — Windtree Therapeutics, Inc. (NasdaqCM: WINT) (“Windtree” or the “Company”), a biotechnology and medical device company focused on advancing multiple late-stage interventions for acute cardiovascular and pulmonary disorders, today announced it has filed a Track One prioritized application with the United States Patent and Trademark Office (USPTO) for a patent stemming from an application it filed previously under the Patent Cooperation Treaty (PCT). Under this USPTO program, the new istaroxime patent is expected to receive examination and final disposition within one year of priority status being granted, rather than the customary three years of examination anticipated by the USPTO for non-prioritized examinations.
Windtree is taking steps to strengthen the istaroxime patent estate since it is the Company’s lead pipeline asset. “With such high unmet need for patients in the disease areas we are studying istaroxime, we are focusing on ensuring our patent estate has the most protection possible. If we are successful in our clinical studies and eventually gain regulatory approval, our plan is for istaroxime to be well prepared and protected in the commercialization stage,” said Craig Fraser, CEO and President of Windtree. Istaroxime is currently being developed in early cardiogenic shock and in acute heart failure (AHF).
Click the button below to read the entire Press Release:
Discover What Sets TrialStat Apart From Ordinary Data Management
Click the image or button below to explore our interactive infographic which illustrates the comprehensive and unique capabilities of the TrialStat eClinical Suite.
Request Your Demo Today!
From rapid database build through database lock, we deliver consistent quality on-time and on-budget. Ready to upgrade your eClinical toolkit?